The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

NCT07272265 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Atezolizumab & Bevacizumab
PROCEDURE: FOLFOX-HAIC

Sponsor

Sun Yat-sen University